Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00411047
What this trial is testing

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Massachusetts General Hospital 34
Testing effectiveness (Phase 2)Looking for participantsNCT06192849
What this trial is testing

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Juan LI, MD 20
Testing effectiveness (Phase 2)Study completedNCT04426825
What this trial is testing

Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 23
Not applicableStudy completedNCT06595498
What this trial is testing

Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer

Who this might be right for
Carcinoma, Non-small Cell Lung Cancer (NSCLC)
Istituto Oncologico Veneto IRCCS 130
Testing effectiveness (Phase 2)UnknownNCT03396185
What this trial is testing

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Who this might be right for
EGFR Gene MutationNon Small Cell Lung Cancer Stage IIIANon Small Cell Lung Cancer Stage IIIB
Betta Pharmaceuticals Co., Ltd. 30
Large-scale testing (Phase 3)Ended earlyNCT04427072
What this trial is testing

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 22
Not applicableStudy completedNCT00899756
What this trial is testing

Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 50
Post-approval studies (Phase 4)Study completedNCT02514174
What this trial is testing

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Who this might be right for
Carcinoma, Non-Small-Cell LungErbB Receptors
Boehringer Ingelheim 25
Large-scale testing (Phase 3)Study completedNCT01024413
What this trial is testing

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Who this might be right for
Thoracic Neoplasms
Chinese Society of Lung Cancer 256
Testing effectiveness (Phase 2)UnknownNCT03050437
What this trial is testing

A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Samsung Medical Center 96
Testing effectiveness (Phase 2)UnknownNCT02960607
What this trial is testing

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Chinese Academy of Medical Sciences 25
Testing effectiveness (Phase 2)WithdrawnNCT02297425
What this trial is testing

Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Who this might be right for
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer
Large-scale testing (Phase 3)Study completedNCT01667562
What this trial is testing

Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 375
Testing effectiveness (Phase 2)UnknownNCT03799094
What this trial is testing

Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Clifford Hospital, Guangzhou, China 150
Large-scale testing (Phase 3)Active Not RecruitingNCT06074588
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 556
Not applicableStudy completedNCT02047903
What this trial is testing

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 161
Large-scale testing (Phase 3)Study completedNCT03653546
What this trial is testing

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationBrain Metastases
Alpha Biopharma (Jiangsu) Co., Ltd. 492
Not applicableNot Yet RecruitingNCT05698264
What this trial is testing

A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationImmune Checkpoint Inhibitor
Nir Peled 50
Testing effectiveness (Phase 2)Looking for participantsNCT04486833
What this trial is testing

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Who this might be right for
Carcinoma, Non-Small Cell Lung
Genprex, Inc. 158
Testing effectiveness (Phase 2)UnknownNCT03151161
What this trial is testing

Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Lung, Carcinoma
Sun Yat-sen University 118
Next Page